Does EFSA statement on Monacolin content of nutraceutical combinations impair their lipid lowering effect? The LopiGLIK experience
Abstract Background Monacolin-K, the active component of red yeast rice (RYR), reduces cholesterol by inhibiting HMG-CoA reductase. Following safety concerns, the European Food Safety Authority (EFSA) recommended limiting Monacolin-K intake to less than 3 mg/day due to adverse effects at higher dose...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | Clinical Diabetes and Endocrinology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40842-024-00204-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|